| Synonyms: | |
| Status: | Phase 2 |
| Entry Type: | Small molecule |
| Molecule Category: | UNKNOWN |
| UNII: | ANR9OP1V17 |
| InChI Key | GTUIQNHJSXQMKW-UHFFFAOYSA-N |
|---|---|
| Smile | |
| InChI |
|
| Property Name | Value |
|---|---|
| Molecular Formula | C11H13ClN2O2 |
| Molecular Weight | 240.69 |
| AlogP | 1.22 |
| Hydrogen Bond Acceptor | 3.0 |
| Hydrogen Bond Donor | 1.0 |
| Number of Rotational Bond | 1.0 |
| Polar Surface Area | 45.48 |
| Molecular species | BASE |
| Aromatic Rings | 1.0 |
| Heavy Atoms | 16.0 |
| Action | Mechanism of Action | Reference |
|---|---|---|
| AGONIST | Neuronal acetylcholine receptor; alpha4/beta2 agonist | PubMed |
| Targets | EC50(nM) | IC50(nM) | Kd(nM) | Ki(nM) | Inhibition(%) | |
|---|---|---|---|---|---|---|
|
Ion channel
Ligand-gated ion channel
5HT3 receptor
|
- | - | - | 700 | 87 | |
|
Ion channel
Ligand-gated ion channel
Nicotinic acetylcholine receptor
Nicotinic acetylcholine receptor alpha subunit
|
4900-4900 | - | - | 30-30 | - | |
|
Ion channel
Ligand-gated ion channel
Nicotinic acetylcholine receptor
Nicotinic acetylcholine receptor beta subunit
|
4900-4900 | - | - | 30-30 | - |
| Mesh Heading | Maximum Phase | Mesh ID | Reference |
|---|---|---|---|
| Alzheimer Disease | 2 | D000544 | ClinicalTrials |
| Attention Deficit Disorder with Hyperactivity | 2 | D001289 | ClinicalTrials |
| Resources | Reference |
|---|---|
| ChEMBL | CHEMBL2179529 |
| FDA SRS | ANR9OP1V17 |
| SureChEMBL | SCHEMBL584395 |